Their effect on the peripheral immune inflammation may be huge
This asset is highly complementary to our Phase 3 FSGS program and broadens our development footprint across the kidney disease continuum, from acute injury through to chronic disease." Dr Nina Webster, CEO & Managing Director, Dimerix Limited #Dimerix #KidneyDisease #RareDisease #Biopharma #DrugDevelopment #ClinicalTrials #Nephrology #PrecisionMedicine #HealthcareInnovation #Biotech To view or add a comment, sign in ICYMI: Early phase 1 data from Bambusa Therapeutics suggests #BBT001 delivered rapid, durable improvements in atopic dermatitis severity and itch, with sustained biomarker suppression, favorable safety, and the potential for dosing as infrequently as every 3 months
Together we decide whether Tirzepatide is an appropriate option
Clinical Test Completed
While most bariatric surgeries are minimally invasive, they still are tremendously disruptive, requiring patients to interrupt their schedules, miss work, substantially change their diets and curtail calorie consumption, and there can be complications and side effects
Aftercare Theres no downtime
